Ergot Alkaloids and Related Compounds

Abstract

I Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application -- II Chemical Background -- A. Occurrence, Biosynthesis, and Production -- B. Structure and Synthesis of the Natural Alkaloids -- C. Chemical Modifications in the Lysergic Acid Half of Ergot Alkaloids -- D. Chemical Modification in the Peptide Part of Ergot Alkaloids -- E. Some Analytical Tools for the Determination of Ergot Alkaloids -- F. Subject Index -- G. References -- III Basic Pharmacological Properties -- A. Introduction -- B. Actions of Ergot Alkaloids at 5-HT Receptors -- C. Actions of Ergot Alkaloids at Dopamine Receptors -- D. Actions of Ergot Alkaloids at Adrenoceptors -- E. The Shape of Ergotamine and Dihydroergotamine in Relation to Their Interaction With?-Adrenoceptors -- F. Actions of Ergot Alkaloids at Acetylcholine Receptors -- G. Actions of Ergot Alkaloids at Histamine Receptors -- H. Interaction of Ergot Alkaloids With Prostaglandins -- J. Stimulation of Smooth Muscle by Ergot Alkaloids Mediated by Miscellaneous Mechanisms -- K. Biochemical Identification of Specific Binding Sites for Ergot Alkaloids -- L. References -- IV Effects on the Uterus -- A. Introduction -- B. Actions on Uterine Motor Activity -- C. References -- V Actions on the Heart and Circulation -- A. Actions on Systemic Blood Pressure -- B. Hemodynamic Effects -- C. Effects on Regional Hemodynamics -- D. Actions on the Heart -- E. Pharmacologic Basis for the Clinical Use of Ergot Alkaloids -- F. References -- VI Effects on the Central Nervous System -- A. Introduction -- B. Early Evidence of Central Effects -- C. Whole-Animal Studies -- D. Synaptic Transmission: Catecholaminergic Mechanisms -- E. Synaptic Transmission: Serotoninergic Mechanisms -- F. Brain Metabolism -- G. References -- VII Clinical Pharmacology of Ergot Alkaloids in Senile Cerebral Insufficiency -- A. Introduction -- B. Terminology, Etiology, and Pathology of the Aging Process of the Brain -- C. Research Techniques Used in Clinical Pharmacologic Studies of Ergot Alkaloids in Senile Cerebral Insufficiency -- D. Results of Clinical Pharmacology Studies With Ergot Alkaloids -- E. Summary -- F. References -- VIII Some Compounds With Hallucinogenic Activity -- A. Introduction -- B. Discovery of LSD -- C. Effects of LSD in Man -- D. Clinical Applications of LSD -- E. LSD Analogues Tested in Man -- F. Cross-Tolerance -- G. References -- IX Influence on the Endocrine System -- A. Animal Data -- B. Human Data -- C. References -- X Metabolic Effects -- A. Introduction -- B. In Vitro Systems -- C. Intact Animals and Men -- D. Various Actions of Ergot Alkaloids -- E. References -- XI Biopharmaceutical Aspects. Analytical Methods, Pharmacokinetics, Metabolism and Bioavailability -- A. Introduction -- B. Assay of Ergot Alkaloids -- C. Pharmacokinetics -- D. Metabolism -- E. References -- XII Toxicologic Considerations -- A. Introduction -- B. Systemic Toxicity -- C. Effects on Reproductive Processes -- D. Potential Genetic Effects -- E. Interactions Leading to Enhanced Toxicity -- F. Summary -- G. References -- Authors Index.